Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML
Launched by NANFANG HOSPITAL, SOUTHERN MEDICAL UNIVERSITY · Jun 7, 2020
Trial Information
Current as of June 22, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with rrAML Patients with the age of 18-65 years old
- Exclusion Criteria:
- • Any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure)
- • Patients with any conditions not suitable for the trial (investigators' decision)
About Nanfang Hospital, Southern Medical University
Nanfang Hospital, affiliated with Southern Medical University, is a leading medical institution in China renowned for its comprehensive clinical services and commitment to advancing healthcare through research and education. As a clinical trial sponsor, Nanfang Hospital leverages its state-of-the-art facilities and a multidisciplinary team of expert researchers to conduct innovative studies aimed at improving patient outcomes and contributing to the global medical community. The hospital's focus on ethical standards and patient safety ensures that all trials are conducted with the highest level of integrity and scientific rigor.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, Guangdong, China
Patients applied
Trial Officials
Qifa Liu
Principal Investigator
Nanfang Hospital, Southern Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials